Mary Tanner - Evotec AG Insider

EVOTF -- USA Stock  

USD 20.25  0.60  3.05%

  Executive
Ms. Mary C. Tanner was Member of the Supervisory Board of Evotec AG since January 19 2005. She has devoted 22 years to the health care and consumer products industry as Senior Managing Director at Bear Stearns and Lehman Brothers both global investment banks. In 2004 Ms. Tanner founded Life Sciences Partners which specializes in healthcare investment and advisory work following her retirement from Bear Stearns in the same year. During her 22 years at Bear Stearns and Lehman Ms. Tanner led or supervised over 575 transactions including 220 mergers acquisitions and divestitures. Ms. Tanner also developed a specialization in the biotechnology industry as it emerged over the last 20 years. She was NonExecutive Member of the Board of Directors at Synvista Therapeutics Inc. Montvale. Ms. Tanner received her university degree from Harvard in 1973 in philosophy and related fields.
  Executive Since 2005      
49 40 5 60 81 0  http://www.evotec.com

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, President of the Management Board, CEO
Claus Braestrup, Member of the Supervisory Board
Michael Shalmi, Member of the Supervisory Board
Mario Polywka, COO and Member of Management Board
Mary Tanner, Member of the Supervisory Board
Roland Oetker, Deputy Chairman of the Supervisory Board
Andreas Pinkwart, Member of the Supervisory Board
Paul Herrling, Member of the Supervisory Board
Colin Bond, CFO and Member of Management Board
Cord Dohrmann, Chief Scientific Officer and Member of Management Board
Iris LoewFriedrich, Member of the Supervisory Board
Bernd Hirsch, Member of the Supervisory Board
Enno Spillner, CFO, Member of the Management Board
Elaine Sullivan, Member of the Supervisory Board
Wolfgang Plischke, Chairman of the Supervisory Board

Stock Performance Indicators

Current Sentiment - EVOTF

Evotec AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Evotec AG. What is your opinion about investing in Evotec AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">